LVTX LAVA Therapeutics N.V. Company Assets

LVTX (lavatherapeutics.com) - company brandmark

LAVA Therapeutics N.V. (LVTX) generates revenue from partnership royalties for antibody development and research in T-cell therapy. This chart of total asset value, which currently stands at 67.64, confirms the financial base. Growth is driven by strict control over biocomponent deliveries via express services, which eliminates trial downtime. Furthermore, margin stability is supported by the diversification of raw material supply chains in the production of bispecific drugs.

LVTX - Lava Tx Company Total Assets over the range 07/04/2022 - 12/06/2025

Analytical breakdowns and data insights for company lavatherapeutics.com (LVTX)

- stock quotes and analyst forecast:
Share Price LAVA Therapeutics|LVTX - Price Target Chart
- market capitalization data:
Market Value LVTX|LVTX - Total Company Value
- balance sheet equity data:
Equity per Share LAVA Therapeutics|LVTX - Book Capitalization|Market Cap to Net Assets Ratio lavatherapeutics.com|LVTX - Aggregate Company Assets
- debt and liquidity details:
Debt to Capital LAVA Therapeutics N.V.|LVTX - Long-Term Debt to Equity|Short-Term Debt to Equity LAVA Therapeutics|LVTX - Company Debts|Debts to Book Value LVTX|LVTX - Company Long-Term Debts|Short-Term Indebtedness LAVA Therapeutics|Immediate Liquidity lavatherapeutics.com
- earnings and market ratios statistics:
LVTX - Net Income
Basic company analysis:LVTX Lava Tx
Signature product of LAVA Therapeutics

Developing innovative gamma-delta T-cell therapy requires colossal resources, which is why the total assets of LAVA Therapeutics N.V. (LVTX) reflect its real potential to create safe anti-tumor drugs. This metric, calculated inversely via ROA, allows investors to assess the market consensus regarding the sustainability of the business model in real-time, avoiding errors when analyzing asset extremes of the company.

Direct competitors

Total Business Assets IBRX|Aggregate Company Assets Immunocore|Company Assets Janux Therapeutics Inc JANX|Aggregate Company Assets Arcus Bio (RCUS)|Zymeworks Biopharmaceuticals - Total Business Assets|Company Total Assets TNGX (Tango Therapeutics)|IOVA - Cumulative Company Assets|IMTX - Aggregate Company Assets|Company Assets Xencor Inc|Compass Bio (CMPX) - Aggregate Company Assets|REPL (Replimune Inc.) - Aggregate Company Assets|Aggregate Company Assets Lyell Immunopharma|Company Assets innate-pharma.com IPHA|Company Total Assets PYXS|cgen.com (CGEN) - Company Balance Sheet Assets|IO Biotech Corp - Cumulative Company Assets|Sutro Biopharma, Inc (STRO) - Company Assets|INKT: Cumulative Company Assets|Aggregate Asset Value HOWL (Werewolf Therapeutics)|IMMX: Company Total Assets|ALXO - Company Total Asset Base|Aggregate Company Assets Cue Biopharma, Inc.|Cumulative Company Assets PDS Biotechnology Corp (PDSB)|Aggregate Company Assets Sonnet BioTherapeutics (SONN)|Cumulative Company Assets MAIABiotech.com MAIA|Liminatus Pharma LLC - Cumulative Company Assets|Company Total Assets NextCure Inc NXTC|LPTX - Aggregate Company Assets|INTS (Intensity Therapeutics) - Total Business Assets|senseibio.com (SNSE) - Aggregate Company Assets|Company Assets therivabio.com (TOVX)|Cumulative Company Assets GRTS|KA - Company Balance Sheet Assets|Cumulative Company Assets NEXI (NexImmune Corp)|Aggregate Business Assets TSBX|Company Total Assets VCNX (Vaccinex, Inc.)|Aggregate Asset Value HARP